Price
No data yet.
Social Signal Score
Analyst Ratings
13 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Richard A. Miller
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 37
- Beta
- 0.86
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 28.66
Financials
Net Income
$-20.34MEBITDA
$-19.36MFree Cash Flow
$-12.28MEPS (diluted)
$-0.22Shares Outstanding (diluted)
92.49M+356.4%Operating Expenses
$21.36MCash & Debt
$202.95MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-15.28M | $-0.19 |
| 2024 | $0.00 | $-62.29M | $-1.02 |
| 2023 | $0.00 | $-27.03M | $-0.56 |
| 2022 | $0.00 | $-41.31M | $-0.89 |
| 2021 | $0.00 | $-43.24M | $-1.03 |
| 2020 | $0.00 | $-6.00M | $-0.20 |
| 2019 | $0.00 | $-46.67M | $-1.49 |
| 2018 | $0.00 | $-46.94M | $-1.71 |
| 2017 | $0.00 | $-55.66M | $-2.72 |
| 2016 | $0.00 | $-36.38M | $-2.36 |
| 2015 | $0.00 | $-31.34M | $-1.54 |
| 2014 | $0.00 | $-176.0K | $-1.03 |
Valuation
CRVShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80-20.00%Social Signal Score
Mentions (8)
- Newsseekingalpha.com·12d ago·Negative
…ighlighted by soquelitinib's potential for durable remission in atopic dermatitis and PTCL. Soquelitinib's post-treatment durability and safety profile differentiate CRVS from competitors, especially as leading OX40 programs have exited the field. CRVS is funded into Q2 2028, with major readouts—including SIERRA-1 and PTCL Phase 3—expected within this runway, reducing near-term financing risk.
View source ↗ - Newsseekingalpha.com·13d ago·Positive
Corvus: 'Strong Buy' On Continued Soquelitinib Advancement And HS Data 1st Half 2027 Corvus Pharmaceuticals maintains a "Strong Buy" rating, driven by soquelitinib's advancing clinical programs in r/r PTCL and autoimmune indications. The phase 3 trial for relapsed/refractory PTCL remains on track, with interim futility analysis in Q1 2027 and topline data expected by year-end 2027. Positive phase 1 AD data and ongoing expansion into HS and asthma, with multiple catalysts, including initial HS da
View source ↗ - Newsseekingalpha.com·16d ago·Positive
Corvus Pharmaceuticals, Inc. (CRVS) Q3 2026 Earnings Call Transcript Corvus Pharmaceuticals, Inc. (CRVS) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·17d ago·Negative
What Corvus Pharmaceuticals (CRVS) Said on Its Q3 Earnings Call Corvus Pharmaceuticals NASDAQ: CRVS reported a wider third-quarter loss as spending on clinical trials increased, while executives outlined a series of 2027 milestones for its lead experimental drug, soquelitinib.
View source ↗ - Newsglobenewswire.com·18d ago·Neutral
…quelitinib T cell lymphoma and atopic dermatitis clinical trials SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that initial data from a Phase 2 clinical trial of soquelitinib for the treatment of patients with autoimmune lymphoproliferative syndrome (ALPS), a rare genetic disease, will be presented in a poster session at the 68th American Society of Hematology (ASH) Annual Me…
View source ↗ - Newsglobenewswire.com·24d ago·Neutral
Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2026 Financial Results on November 5, 2026 SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on November 5, 2026 at 4:30 pm ET (1:30 pm PT) to provide a business update and report third quarter 2026 financial results.
View source ↗ - Newsglobenewswire.com·53d ago·Neutral
Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativa SOUTH SAN FRANCISCO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that enrollment has begun in its Phase 1b clinical trial of soquelitinib for the treatment of patients with hidradenitis suppurativa.
View source ↗ - Newsglobenewswire.com·87d ago·Neutral
…rker data from the soquelitinib Phase 1 atopic dermatitis trial SOUTH SAN FRANCISCO, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the publication of peer-reviewed final data from its Phase 1/1b trial of soquelitinib in patients with T cell lymphoma.
View source ↗
Earnings
Thu, Mar 11(in 4 months)
Consensus estimate $-0.24 per share
Typical surprise -7.1% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$-0.22 vs $-0.19miss
- Thu, Aug 6$-0.19 vs $-0.16miss
- Thu, May 7$-0.15 vs $-0.14miss
- Thu, Mar 12$-0.15 vs $-0.14miss
- Tue, Nov 4$-0.12 vs $-0.14beat
- Thu, Aug 7$-0.10 vs $-0.13beat
Estimates and results for CRVS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CRVS officers and directors.
- Bought
- $13.3m
- Sold
- $9.8m
17 trades
2 trades
- Arcara Jeffreybought
- Arcara Jeffreybought
- Arcara Jeffreybought
- Arcara Jeffreybought
- Moore David Scottbought
- Miller Richard A Mdbought
- Miller Richard A Mdbought
- Orbimed Advisors Llcsold
81 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CRVS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
